Sodium–glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists treatment: variable observations of sequelae on diabetic retinopathy

Abstract

Get full access to this article

View all access options for this article.

References

Kunutsor

Khunti

Seidu

Racial, ethnic and regional differences in the effect of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes: a systematic review and meta-analysis of cardiovascular outcome trials. J R Soc Med. doi: 10.1177/01410768231198442. Epub ahead of print. PMID: 37734450.

Wołos-Kłosowicz

Matuszewski

Rutkowska

Krankowska

Bandurska-Stankiewicz

Will GLP-1 analogues and SGLT-2 inhibitors become new game changers for diabetic retinopathy?

J Clin Med 2022; 11: 6183.

Nugawela

Gurudas

Prevost

Mathur

Robson

Hanif

, et al. Ethnic disparities in the development of sight-threatening diabetic retinopathy in a UK multi-ethnic population with diabetes: an observational cohort study. J Pers Med 2021; 11: 740.